Skip to main
ITRM
ITRM logo

ITRM Stock Forecast & Price Target

ITRM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Iterum Therapeutics PLC is positioned favorably in the pharmaceutical market due to its development of Orlynvah, an innovative oral and intravenous branded penem that effectively targets complicated urinary tract infections (UTIs) caused by drug-resistant bacteria. The company's sulopenem has shown remarkable clinical efficacy in patients with quinolone-resistant infections, demonstrating improvements in overall response rates at key clinical assessment points, which enhances its appeal among healthcare providers. Additionally, the favorable safety profile of sulopenem differentiates it from other antimicrobials, suggesting strong potential for adoption by physicians, which supports a positive outlook for the company's stock.

Bears say

Iterum Therapeutics PLC faces a challenging financial outlook primarily due to depressed forward multiples influenced by current market volatility, indicating a lack of investor confidence in the company's prospects. Additionally, the company’s cash burn may be substantial as pre-commercial activities ramp up, despite the potential for revenue support from partners or collaborative milestone payments. Furthermore, the increasing prevalence of antibiotic-resistant strains of bacteria could limit the overall market demand and therapeutic applicability for Orlynvah, complicating the company's growth potential in an already competitive landscape.

ITRM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Iterum Therapeutics Plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Iterum Therapeutics Plc (ITRM) Forecast

Analysts have given ITRM a Strong Buy based on their latest research and market trends.

According to 1 analysts, ITRM has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Iterum Therapeutics Plc (ITRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.